Estrella Immunopharma, Inc. 8-K

What Happened Estrella Immunopharma, Inc. announced in an 8-K that on January 7, 2026 it received a letter from Nasdaq’s Listing Qualifications Department stating the company is not in compliance with Nasdaq Listing Rule 5620(a) because it did not hold an annual shareholders’ meeting within the required timeframe. Nasdaq referenced the compliance plan procedures under Rule 5810(c)(2)(G) and gave the company 45 calendar days to submit a plan to regain compliance. The company intends to file a compliance plan within that window and is planning an annual meeting in April 2026; it will consult with Nasdaq about whether that meeting will restore compliance.

Key Details

• Date of Nasdaq letter: January 7, 2026.
• Noncompliance cited: Nasdaq Listing Rule 5620(a) (annual meeting requirement).
• Deadline: 45 calendar days to submit a compliance plan under Nasdaq procedures (Rule 5810(c)(2)(G)).
• Company action: Plans to submit a compliance plan and convene an annual meeting in April 2026; the letter does not currently affect listing or trading.

Why It Matters This filing signals a Nasdaq compliance issue that could, if unresolved, lead to additional Nasdaq actions (including possible delisting procedures). For investors, the immediate impact is limited — the company’s securities continue to trade on Nasdaq — but the outcome depends on Nasdaq’s review of the company’s compliance plan and any required corrective steps. Investors should monitor future updates about the compliance plan, the April 2026 meeting, and any Nasdaq determinations.